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Real-time assessment of nanoparticle-mediated
antigen delivery and cell response†
Carlota A. Cunha-Matos,a Owain R. Millington,b
Alastair W. Warkc and Michele Zagnoni*d
Nanomaterials are increasingly being developed for applications in biotechnology, including the delivery of
therapeutic drugs and of vaccine antigens. However, there is a lack of screening systems that can rapidly
assess the dynamics of nanoparticle uptake and their consequential effects on cells. Established in vitro ap-
proaches are often carried out on a single time point, rely on time-consuming bulk measurements and are
based primarily on populations of cell lines. As such, these procedures provide averaged results, do not
guarantee precise control over the delivery of nanoparticles to cells and cannot easily generate information
about the dynamics of nanoparticle–cell interactions and/or nanoparticle-mediated compound delivery.
Combining microfluidics and nanotechnology with imaging techniques, we present a microfluidic platform
to monitor nanoparticle uptake and intracellular processing in real-time and at the single-cell level. As
proof-of-concept application, the potential of such a system for understanding nanovaccine delivery and
processing was investigated and we demonstrate controlled delivery of ovalbumin-conjugated gold nano-
rods to primary dendritic cells. Using time-lapse microscopy, our approach allowed monitoring of uptake
and processing of nanoparticles across a range of concentrations over several hours on hundreds of sin-
gle-cells. This system represents a novel application of single-cell microfluidics for nanomaterial screening,
providing a general platform for studying the dynamics of cell–nanomaterial interactions and representing a
cost-saving and time-effective screening tool for many nanomaterial formulations and cell types.
Introduction
Nanomedicine is a rapidly emerging and promising field for
diagnostic and therapeutic applications.1–3 Central to the ef-
fective development of nanoparticles (e.g. polymeric, lipidic,
and inorganic) for such purposes is the ability to systemati-
cally explore how particle properties and environmental fac-
tors influence cellular uptake mechanisms, intracellular pro-
cessing, compound delivery, and inherent toxicity.1,4 However,
standard procedures for testing nanomaterials are often
based on end-point measurements and studies are generally
limited to a narrow range of parameters (e.g. a specific cell
type or nanomaterial formulation), making it difficult to
achieve global conclusions.4–7 Additionally, information on
the dynamics of nanoparticle uptake and subsequent cellular
processing is of utmost importance when investigating cell
responses, as the complexity of cell function is dictated by
underlying dynamic processes8 and uptake pathways can
strongly influence functional outcomes.9,10 This highlights
the need to develop technological tools that can enable evalu-
ation of cell–nanoparticle interactions with the appropriate
temporal and spatial resolutions.
Lab-on-a-chip and microfluidic technologies offer such
opportunities,6,7,11–15minimising sample volumes andmaximising
control over the manipulation of particles suspended in lami-
nar flows. Organ,16 tumour17,18 and body-on-a-chip19 studies
have shown the importance of producing physiologically rele-
vant microenvironments when testing nanomaterials with re-
spect to static flow well-plate systems, while single-cell micro-
fluidic approaches provide data from a single device with a
throughput comparable to that of standard flow cytometry.20–23
Additionally, microfluidic techniques are compatible with live
cell microscopy and can facilitate nanoparticle tracking with
intracellular resolution, therefore providing information on the
effect of nanomaterials at the single-cell level6,7,12 and in-
sight into the heterogeneity of responses to nanomaterials.24,25
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One application benefiting from such an approach is the
assessment of antigen delivery to dendritic cells.26 Den-
dritic cells are a privileged target for vaccine delivery due to
their role in the initiation of the immune response through
antigen internalization, processing and presentation to
lymphocytes.26–28 Gold nanoparticles have great potential as
vaccine carriers due to their biocompatibility and potent ad-
juvant ability29,30 and successful targeting to dendritic cells
may allow for increased activation at lower antigen dose, po-
tentially reducing side-effects and vaccine production
costs.26,29,31 Additionally, anisotropic particles (such as gold
nanorods) have extremely versatile optical properties which
can be tuned for specific applications, originating highly
specific and stable substrates for intracellular multimodal
imaging with sensitivities at the single nanoparticle
level.32,33 To date, microfluidics has shown great promise
for providing tools to investigate immunological func-
tions,34 from cell migration35,36 to lymphocyte function37,38
and cell pairing.39 As new nanomaterials emerge for a vari-
ety of immune-based applications, there is a growing need
for microfluidic tools that enable the assessment of the dy-
namics involved in the intracellular processing of antigen
via nanoparticle-mediated delivery.6,26,28
Taking nanoparticle-mediated antigen delivery as a proof-
of-concept application, a microfluidic platform was developed
to monitor in real-time hundreds of primary, murine bone
marrow-derived dendritic cells at the single-cell level follow-
ing exposure to a range of concentrations of ovalbumin-
conjugated gold nanorods. Time-lapse microscopy enabled
specific aspects of cell function to be monitored: nanoparticle
uptake was proportional to the fluorescence intensity of a dye
encapsulated in the nanorods, while antigen processing was
identified by intracellular enzymatic cleavage of ovalbumin-
conjugated fluorophores. This novel combination of single-
cell microfluidics with customised nanorods and imaging
techniques for nano-vaccine screening yielded outcomes that
provide unique information regarding the dynamics of nano-
particle/single-cell interactions and nanoparticle-mediated
antigen delivery.
Experimental protocols
Preparation and characterisation of gold nanorod conjugates
Synthesis of gold nanorods (NRs) was performed using an
adapted version40,41 of the seed-mediated growth method
using cetyltriethylammonium bromide (CTAB),42,43 followed
by fluorescence/Raman reporter dye incorporation41 and poly-
electrolyte wrapping44 (detailed procedures described in
ESI†). The design and optical characterisation of the NR con-
jugates used in this study are described in Fig. S1.† The devel-
oped NRs were biocompatible at the concentrations used
(Fig. S1b†) and emitted fluorescence at >650 nm when ex-
cited at 633 nm (Fig. S1c†) due to the incorporated reporter
dye. The colloidal suspensions of polymer-wrapped NRs were
monitored for >6 months with no change in the UV-vis or
SERRS properties, indicating very good stability of the CTAB/
dye layer following polymer wrapping, as previously de-
scribed.32,41 To assess the NR suitability for use in cellular
environments, colloidal stability in serum-containing culture
medium was tested for nanoparticles with different polyelec-
trolyte coatings (procedures in ESI†). Following this (Fig. S1e
and f†), only the three-layer polymer configuration (PSS-
PDDAC-PSS) was used, which ensured colloidal stability in
both the cell culture and microfluidic environments.
Preparation and analysis of dendritic cells
Bone marrow-derived dendritic cells were generated from
BALB/c or Ly5.1 congenic mice (maintained in accordance
with local ethical committee and UK Home Office guidelines)
as previously described.45 After culture for 7–8 days, cells
were routinely checked for specific surface phenotype
(CD11c) and activation (CD40) markers [eBioscience, UK]
using flow cytometry, with typically over 90% of the cells
being CD11c positive in the samples used (Fig. S2†). Off-
chip testing of NR conjugates for biocompatibility and
antigen delivery was performed using the procedures de-
scribed in ESI.† DQ Ovalbumin (DQOVA) is an ovalbumin
conjugate containing a quenched BODIPY fluorescence dye
which becomes fluorescent upon cleavage by intracellular
proteases, and is thus a good indicator of antigen processing
by dendritic cells.46 Therefore, NR–DQOVA conjugates were
produced and tested off-chip with cells, as an initial assess-
ment of the coating procedure and of cell response under dif-
ferent experimental conditions (i.e. to optimize the range of
concentrations and incubation times) prior to their use in
the microfluidic device. Flow cytometry was performed to ob-
tain end-point measurements of cell samples exposed to dif-
ferent concentrations of NR–DQOVA and soluble DQOVA for
different periods of time. Confocal microscopy was used to
assess internalization of NR–DQOVA conjugates and antigen
processing. To assess the functionality of the developed NR
conjugates, NRs were conjugated to non-labelled ovalbumin
(OVA) and added to dendritic cells and OVA-specific OT-II T
cells to assess whether antigen on the NR surface was
processed and presented to T cells to initiate an adaptive im-
mune response. T cell activation was measured by CD69 sur-
face marker expression on the surface of CD4+ T cells using
flow cytometry, while ELISA was used to assess cytokine
(interferon-γ) production.
Cell trapping, nanorod delivery and real-time cell monitoring
in the microfluidic device
Microfluidic devices, consisting of three inlets, one outlet
and one trap array chamber, were fabricated using standard
photo- and soft-lithography procedures, as described in ESI.†
For time-lapse imaging, the devices were inserted in a Tokai
Hit INUB-WELS-F1 microscope stage incubator [Tokai, Japan]
and kept at 37 °C, 5% CO2 and high humidity conditions for
the duration of the experiments. Devices were sequentially
primed manually with 70% isopropanol and deionised water
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prior to cell injection. Syringe pumps [Aladdin 220, World
Precision Instrument, UK] were connected to the device via
microbore polytetrafluoroethylene (PTFE) tubing [Cole
Parmer, UK]. Dendritic cells at 1.5–3 × 106 cells per ml in
complete RPMI (see ESI†) were withdrawn into the PTFE
tubing using a syringe pump, and subsequently loaded into
the device at 1.5 μl min−1 for at least 2 hours to allow for
settling of the cells into a chamber hosting an array of
microtraps. After trapping, a suspension of 400 pM (approx-
imate optical density of 2) NR–DQOVA conjugates in com-
plete RPMI was delivered into the trap array at 0.5 μl min−1
through one side inlet, whilst the contralateral inlet was
used to dispense medium at the same flow rate, forming an
adjustable range of NR concentrations across the trap array
chamber (Fig. S3†). This flow condition was maintained for
2 h, after which culture medium was continuously perfused
through the array of cells for the remaining duration of the
experiment at 0.5 μl min−1. Time-lapse bright-field and fluo-
rescence imaging (20× objective – 0.323 μm per pixel, 32
tiles acquired every 5 minutes for 8 hours) covering over a
third of the trapping array was performed using an auto-
mated Zeiss Axiovert Observer inverted microscope with
Colibri 2 LED illumination, AxioCam camera and Zen 2 Pro
acquisition software.
Single-cell data analysis
Microscopy images were analysed using Zen 2 Pro software.
Circular regions of interest (ROI) were defined around each
trapped cell and corrected for position if the cells moved over
time, ensuring single-cell data consistency over the course of
the experiment. Cells adhering to the outside of the traps
were not considered. The mean fluorescence intensity (MFI)
for each ROI was then extracted and analysed. For analysis of
cell population response with respect to nanoparticle concen-
tration, ROI data was grouped into three regions of the array
containing approximately the same number of traps
according to the flow conditions: a null NR concentration re-
gion, a medium NR concentration region, corresponding to
the particle concentration gradient, and a high NR concentra-
tion region. Background correction was done using a circular
ROI situated outside the traps in the null concentration re-
gion and a 5th-degree polynomial curve was used to fit the
data.
Results
The microfluidic device consisted of three inlets, a trapping
chamber containing an array of 1512 traps, and one outlet
(Fig. 1a). One inlet was used to flow a cell suspension into
Fig. 1 Schematic representation of the microfluidic system and protocol developed for investigating cell–nanoparticle interactions and real-time
antigen processing. (a) Dendritic cells (a-i – confocal fluorescence image of dendritic cells with the membranes stained with cholera-toxin-B
(green) and DAPI-stained nucleus (blue). Scale bar = 10 μm) and nanorods (a-ii – SEM image of gold NRs with longitudinal λmax of 765 nm. Scale
bar = 100 nm) were sequentially injected into a microfluidic device containing an array of microtraps (a-iii – SEM image of the PDMS microtrap ar-
ray. Scale bar = 40 μm). (b, c, d-i) Schematic representation of the key temporal aspects of the microfluidic protocol: cell trapping, NR delivery and
antigen processing, respectively, from top to bottom. Cells are represented in grey: they become red when in contact with NRs and turn green af-
ter antigen processing. (b, c, d-ii) Phase contrast and composite images of the trapping array (scale bar = 100 μm) corresponding to the time points
of the schematics in b, c, d-i. (b, c, d-iii) Fluorescence intensity profile showing responses to NR uptake and antigen processing across the width of
the array chamber for the time points corresponding to the schematics in b, c, d-i. Each data point represents the mean fluorescence intensity
(MFI) (background corrected) of single-cell ROIs located in the same vertical region of the chamber over five rows ± standard error of the mean (S.
E.M.), with red representing NR fluorescence measured at 625 nm excitation and green representing DQOVA fluorescence measured at 488 nm
excitation.
Lab on a ChipPaper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
0 
Ju
ly
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
3/
09
/2
01
6 
14
:5
1:
19
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Lab Chip, 2016, 16, 3374–3381 | 3377This journal is © The Royal Society of Chemistry 2016
the trap array chamber while the others were subsequently
utilized to produce a NR concentration gradient across the
width of the array. Each trap had an inner width of 20 μm
and constituted a low shear stress pocket (<0.05 dyn cm−2),
thus inducing cell trapping without damaging the cell mem-
brane.21 The device and protocol developed resulted in the
successful trapping of hundreds of dendritic cells at the
single-cell level. Typically, for the cell concentration and flow
rates used, 17% of the total trap sites remained empty or
contained cell debris, 68% contained single-cells and 15%
contained 2 or 3 cells. By using primary dendritic cells, a
greater variability in cell shape, size and activation status is
present with respect to the use of cell lines, which leads to
challenges in achieving uniform cell trapping. Overall, con-
sidering traps containing between 1 and 3 cells, 83% trap-
ping efficiency was obtained in our system, with all of the
trapped cells that could be individually tracked. During injec-
tion, cells retained a round shape and, within 15 minutes,
displayed characteristic branched projections (or dendrites),
thus confirming their viable state. Cells could be cultured in
the microfluidics at 37 °C and 5% CO2 under continuous per-
fusion in growth medium, with no detectable damage to the
cells for up to 24 hours. Viability staining was performed on
cells after 24 hours of culture in the trapping chamber and
following exposure to NRs. Results (Fig. S4†) show the bio-
compatible nature of the microfluidic setup, protocols and
NRs used.
Following successful cell trapping in the microfluidic array
(Fig. 1b), wide-field images of approximately 550 traps were
acquired every five minutes over eight hours. Delivery of NR–
DQOVA conjugates was initiated 30 minutes after starting
time-lapse recording and continued for approximately two
hours (Fig. 1c), with the protocol developed resulting in the
left side of the array receiving no nanoparticles, the middle
area receiving a concentration gradient of nanoparticles and
the right side receiving a uniform concentration of nano-
particles (Fig. S3†). Subsequently, perfusion with medium al-
one was continued until the end of the experiment (Fig. 1d).
Phase contrast was used to identify cells in traps, whilst the
fluorescent signals corresponding to NR uptake and antigen
processing were monitored using the red (625 nm excitation)
and green (488 nm excitation) channels, respectively.
Fig. 1(b, c, d-iii) shows the average fluorescence intensity
profile for single-cells within five rows across the entire
width of the array. As expected, during nanoparticle deliv-
ery, there was an increase in red fluorescence intensity on
the high NR concentration region (right side in Fig. 1c-iii).
This was followed by an increase in green fluorescence
intensity as the dendritic cells processed the delivered anti-
gen, whilst the NR-deficient area had no detectable fluores-
cence signal (Fig. 1d-iii). For analysis of the time-dependence
of single-cell response, the trap array was divided into three
regions containing approximately the same number of traps,
according to the level of exposure to different nanoparticle
conjugate concentrations. Fig. 2 shows the MFI of all the
single-cells in each of these regions, with a peak in red fluo-
rescence (b-i, c-i) marking the highest concentration of NR
exposure to the cells, followed by a gradual increase in green
fluorescence corresponding to antigen processing as mea-
sured by DQOVA cleavage (b-ii, c-ii). These results clearly
demonstrate the capacity of our system for monitoring the
time- and dose-dependent uptake and processing of antigen-
coated nanoparticles in real-time across a population of
trapped cells.
Following assessment of the population response for dif-
ferent NR–DQOVA concentrations delivered, individual cells
were analysed in order to assess cell response heterogeneity,
as well as the dynamics of NR uptake and processing at the
single-cell level. To do this, heatmaps were produced
representing the level of DQOVA processing for all the single-
cell ROIs (Fig. 3a, b, c,-i) according to their position in the ar-
ray, showing clear variability in terms of amount of antigen
processed and speed of response. Example of cell heterogene-
ity in response to antigen delivery is also shown for single-
cells in five different traps exposed to the same concentration
of NRs (Fig. 4a). Additionally, fluorescent intensity traces of all
the individual cells under analysis were extracted and examples
are shown for each of the array regions (Fig. 3a, b, c,-ii and iii).
Video S1† shows representative time-lapse images for cells in
these three regions.
Subsequently, we investigated whether an increasing NR
uptake correlated with enhanced antigen-processing. For this
analysis, cells were gated as NR+DQOVA+ based on their fluo-
rescence intensities above background level for both chan-
nels to identify cells that both took up nanoparticles and
Fig. 2 Representative plots of averaged single-cell responses follow-
ing nanoparticle uptake and antigen processing. Circular ROIs were
drawn around individual cells for data acquired every 5 minutes over
8 hours. For analysis purposes, three regions were defined according
to different nanoparticle concentrations: (a) null concentration (N =
151), (b) medium concentration (N = 203) and (c) high concentration
(N = 171) regions, as per the illustrated nanoparticle concentration gra-
dient profile (top). Graphs show the response of single-cells in each of
these regions. (a, b, c-i) Average NR fluorescence intensity (back-
ground corrected) measured at 625 nm excitation ± S.E.M. (a, b, c-ii)
Average DQOVA fluorescence intensity (background corrected) mea-
sured at 488 nm excitation ± S.E.M.
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processed antigen. This double positive population repre-
sented 0.6%, 43.3% and 84.3% of total cells in the null, me-
dium and high concentration regions, respectively. Fig. 4b
shows the intensity of antigen processing by gated single-
cells with different levels of NR uptake. These data suggest
that an increased accumulation of NRs in cells correlated
with higher processing of DQOVA.
The dynamics of vaccine uptake, processing and presenta-
tion can have a key role in determining the magnitude and
type of immune response induced. Therefore, we measured
the lag time between the peak of NR uptake and antigen pro-
cessing (Fig. 4c) for all the gated cells. The results (Fig. 4d)
indicate that despite being exposed to different concentra-
tions and acquiring different amounts of NR conjugates, the
time delay between NR uptake and antigen processing
followed a Gaussian distribution, with the standard deviation
of the fitted curve (continuous line in Fig. 4d) being represen-
tative of response heterogeneity.
While microfluidic techniques have been used to perform
lymphocyte activation and cell pairing experiments,37–39 the
scope of this work is to provide a general platform for screen-
ing nanoparticle conjugates for nanomedicine research.
Therefore, following validation of nanoparticle-mediated de-
livery of antigen to dendritic cells on-chip, off-chip tests were
performed to confirm that the antigen was not only
processed (quantified using DQOVA in Fig. 1–4), but also
presented to T cells. For this, OVA-specific T cells were
allowed to interact with dendritic cells exposed to various
concentrations of NR–OVA or OVA only, as described in ESI.†
Analysis using flow cytometry (Fig. 5a) showed significantly
increased expression of CD69 (suggesting recent activation)
on the surface of OVA-specific T cells that were added to
Fig. 3 Comparison of single-cell responses to NR-conjugate delivery in the (a) null, (b) medium and (c) high NR concentration regions of the
microfluidic array. (a, b, c-i) Heatmaps showing processing of DQOVA within individual cell ROIs, where white corresponds to a null response and
dark green is the maximum MFI value across the whole array, with the midpoint (yellow) at the 50th percentile. Examples of single-cell ROIs were
then selected from each area of the microfluidic array and their fluorescence intensity profiles plotted to assess their response patterns. (a, b, c-ii)
Composite fluorescence images of trapped cells for different time points over 8 hours and (a, b, c-iii) MFI plots for the same ROIs over 8 hours,
where red indicates NR exposure, measured at 625 nm excitation, and green indicates DQOVA processing, measured at 488 nm excitation.
Fig. 4 Analysis of single-cell response to antigen processing. (a) Ex-
amples of MFI profiles for DQOVA from six cells in different traps
within the high NR concentration region, showing heterogeneous cell
response to antigen-coated NRs. Traces are coloured according to
intensity as per heatmaps in Fig. 3. (b) Average DQOVA MFI range
(max–min) for gated single-cell ROIs depending on NR MFI range
(max–min) (±S.E.M.; N between 23 and 61 cells; significant differences
determined by one-way analysis of variance test with **p < 0.01, ***p
< 0.001). (c) Illustration of the parameters used for measuring the time
delay (“lag time”) between nanoparticle uptake and antigen processing
(MFI traces) for each individual cell ROI, calculated as the time differ-
ence between NR half-maximum MFI and DQOVA half-maximum MFI
(blue bar). (d) Histogram showing the lag time response for all the
gated single-cell ROIs with damped least-squares Gaussian fit (σ =
0.526) superimposed. Single-cell ROIs shown in (b) and (d) were gated
as NR+ and DQOVA+.
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dendritic cells exposed to NR–OVA, over four separate experi-
ments. Additionally, ELISA data (Fig. 5b) showed that the
same T cells were actively producing high levels of interferon-
γ (IFNγ) after 72 h of co-culture – a cytokine that is only pro-
duced by T cells that have been efficiently activated by anti-
gen-presentation. Together, these data demonstrate that the
NR–OVA conjugates are efficiently delivered to dendritic cells
where they are rapidly processed and NR-associated antigens
can be presented to T cells to induce a specific adaptive im-
mune response.
Discussion
In this study, we present a microfluidic platform to monitor
the controlled delivery of antigen-conjugated nanoparticles to
biologically-relevant, primary dendritic cells, providing a new
methodology to investigate the nanoparticle–cell dynamics
involved in nanoparticle-mediated antigen delivery in a man-
ner not possible using conventional methods.
We have previously shown that the developed gold NR
conjugates provide a highly stable rod-dye combination with
very specific and tunable imaging capabilities,32,41 such as
combined surface-enhanced resonance Raman spectroscopy
(SERRS) and fluorescence microscopy (Fig. S1b and c†). Here,
under the controlled laminar flow conditions provided by
microfluidics, we show how fluorescence microscopy can be
used to assess nanoparticle uptake without requiring addi-
tional fluorescent probes. This highlights the potential of this
system to integrate multimodal imaging capabilities. For ex-
ample, SERRS mapping data was also obtained within the
microfluidic device, following a NR concentration gradient in
the array (Fig. S5†). Good correlation between the fluores-
cence and SERRS measurements of nanoparticle uptake indi-
cates that our approach is amenable to applying more than
one imaging modality for the real-time monitoring of nano-
particle–cell interactions in the future, along with particle
intracellular distribution. For the current application, NRs
were further conjugated to DQOVA, an ovalbumin-dye conju-
gate that becomes fluorescent upon cleavage by intracellular
proteases (commonly used as a marker for antigen process-
ing). This allowed for simultaneous tracking of nanovaccine
uptake and processing by cells using fluorescence
microscopy.
Following successful cell trapping and NR delivery in the
microfluidic device, real time NR uptake and antigen process-
ing data was obtained from 525 trapped single-cells over
8 hours, showing the capabilities of the developed micro-
fluidic platform to provide statistically relevant data, as well
as single-cell resolution over long periods of time. In this
work, approximately 45 000 cells were required for one micro-
fluidic experiment, in comparison with at least 2.4 million
cells used to run the equivalent experiments off-chip in well
plates and in static conditions. This is especially relevant
when dealing with rare or patient-derived cell samples and
further highlights the capabilities of the system as a pre-
screening tool for nanomaterials for clinical applications.
NR delivery was achieved successfully and, in addition to
delivering different particle concentrations simultaneously,
the microfluidic procedure ensured that NR conjugates were
in contact with cells only for a defined amount of time and
under constant flow conditions. Using the proposed micro-
fluidic approach, a more controlled particle delivery to cells
is obtained with respect to that in equivalent well plate exper-
iments. In fact, in the latter, shortly after particle injection
into the wells, NRs sediment at the bottom of the plate and it
is reasonable to assume that the degree of nanoparticle up-
take by cells will depend mostly on their level of activity or
motility within the plate, with the most motile cells inter-
nalising nanomaterial at a greater rate than stationary or less
motile cells (Video S2†). However, this information cannot be
extracted from flow cytometry analysis and presents one of
the disadvantages of performing well plate based experi-
ments. Our data shows that the microfluidic approach pro-
vided information from a cell population comparable to that
obtained with flow cytometry, but allowing for the additional
assessment of the cell–nanoparticle interaction dynamics, as
opposed to end-point measurements of separate samples.
Therefore, the methodology developed here, allowing a con-
trolled amount of NRs to be delivered for a defined period of
time, represents a more relevant in vivo-like delivery environ-
ment than that achieved carrying out experiments in static
conditions.24,47
Differences in NR conjugate concentration delivered
across the array and subsequent differences in antigen pro-
cessing response could be assessed both at the population
Fig. 5 Assessment of NR-mediated immune response generation
compared with soluble ovalbumin. OVA-specific OT-II T cells were in-
cubated with dendritic cells and different NR formulations or soluble
OVA for 72 h. (a) Flow cytometry data of CD4+ T cells showing the MFI
of CD69 as a measure of lymphocyte activation. Data has been
normalised to the unpulsed sample for each separate experiment, for
presentation clarity, and results shown are mean value ± S.E.M. of four
independent experiments. Significant differences to the unpulsed sam-
ple were determined on the absolute MFI values by two-way analysis
of variance with Fisher means comparison (*p < 0.05, **p < 0.01). (b)
ELISA data showing cytokine (IFNγ) production by the T cells. Data is
mean value ± S.D. of technical duplicates. Results show that NR–OVA
conjugates have successfully delivered antigen to the dendritic cells,
which was then presented to T cells to initiate an adaptive immune
response.
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level (Fig. 2) and at the single-cell level (Fig. 3). The hetero-
geneity of time and intensity of cell response to similar
stimuli, as shown in the heatmaps in Fig. 3(a, b, c-i), under-
lines the importance of acquiring single-cell information to
better understand cellular behaviour, as opposed to aver-
aged population responses. Fig. 4a further emphasises the
heterogeneity of response by comparing single-cell traces of
DQOVA fluorescence for cells in the same NR concentration
region. This outcome can be attributed to different degrees
of cell activation, leading to either up-regulation or down-
regulation of uptake mechanisms, as well as viability status,
and its assessment is of vital importance when investigating
cellular response to stimuli.25,39,48 Off-chip confocal imag-
ing showed bright fluorescence of the NR-delivered DQOVA
complexes within the intracellular space (Fig. S6†). Interest-
ingly, DQOVA fluorescence was delocalised from the signal
obtained from NRs, suggesting the antigen molecules could
have detached from the NR surface. Overall, the optical
properties of labelled gold NRs combined with the devel-
oped microfluidic platform have the potential to provide
data on the intracellular processing pathways involved in
nanovaccine delivery and subsequent release of antigen
from the surface of nanoparticles.
Finally, the use of primary cells, that are heterogeneous in
morphology and size, allowed for a more reliable assessment
of cell function when compared to work done with cell
lines.49 Specifically, dendritic cells are involved in key as-
pects of the immune system, internalising pathogens and
foreign materials and initiating adaptive immunity through
presentation of antigen to T cells. This leads to the stimula-
tion of lymphocyte activation, proliferation and differentia-
tion into effector T cells, which are capable of producing cy-
tokines,27 outcomes that were validated using additional
flow cytometry and ELISA measurements for the developed
NR conjugates (Fig. 5). It is worth noting that similar T cell
activation profiles were obtained for an estimated concen-
tration of OVA delivered by NR (∼1 nM, see Methods in
ESI†) that was approximately four orders of magnitude lower
than that of soluble OVA used as a positive control (11 μM).
No T cell activation was elicited by similar low concentra-
tions (1.1 nM) of soluble OVA. This suggests that the NR for-
mulation used may facilitate antigen uptake as well as hav-
ing adjuvant activity, consistently with existing evidence that
polymer-wrapped gold nanorods can act as powerful
adjuvants,30 a valuable feature for the development of effi-
cient nanovaccines.29,50,51 On-chip delivery of a concentra-
tion gradient of 0–222 nM soluble DQOVA was also tested
and provided comparable fluorescent signal to that
obtained with the NR concentration gradient using 400 pM
NR–DQOVA conjugates (∼8 nM DQOVA, Fig. S7†). Overall,
when combined with the microfluidics data described
above, these results demonstrate the important role that
microfluidics can play in the design and efficient optimisa-
tion of new nanovaccine formulations, including assessing
the dose and uptake kinetics, with the future potential to
develop more complex intercellular studies.
Conclusion
This work presents a novel microfluidic approach for studying
the dynamics of cell response to nanomaterials. A nanoparticle-
antigen model was developed to induce the immune response
of primary dendritic cells using a microfluidic platform that pro-
vides high-throughput, real-time information on the cellular–
nanoparticle interactions. The use of biologically-relevant pri-
mary cells has numerous advantages over previous work using
cell lines, especially when translating results towards in vivo de-
velopment. With increasing interest in the application of nano-
technology for the delivery of vaccines and therapeutic drugs,
the real-time cell monitoring platform presented here can greatly
improve the investigation of effects produced by nano-carriers,
providing statistically-relevant information about the dynamics
of intracellular processes underlying the interaction of cells with
different nanomaterial formulations – with applications ranging
from the initial biocompatibility testing to enhanced control over
molecule delivery (for example, through the use of targeting
molecules or pH-dependent delivery systems). Importantly,
the presented platform can be easily adapted for use with dif-
ferent cell types and particle formulations, making it a versa-
tile tool for the initial screening and development of nano-
materials for biomedical applications.
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